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Abstract 
Background: Casticin, the flavonoid extracted from Vitex rotundifolia L, exerts various biological effects, including 
anti‑inflammatory and anti‑cancer activity. The aim of this study is to investigate the effects and mechanisms of cas‑
ticin in human gallbladder cancer cells.
Methods: Human NOZ and SGC996 cells were used to perform the experiments. CCK‑8 assay and colony formation 
assay were performed to evaluate cell viability. Cell cycle analyses and annexin V/PI staining assay for apoptosis were 
measured using flow cytometry. Western blot analysis was used to evaluate the changes in protein expression, and 
the effect of casticin treatment in vivo was experimented with xenografted tumors.
Results: In this study, we found that casticin significantly inhibited gallbladder cancer cell proliferation in a dose‑ and 
time‑dependent manner. Casticin also induced G0/G1 arrest and mitochondrial‑related apoptosis by upregulating 
Bax, cleaved caspase‑3, cleaved caspase‑9 and cleaved poly ADP‑ribose polymerase expression, and by downregulat‑
ing Bcl‑2 expression. Moreover, casticin induced cycle arrest and apoptosis by upregulating p27 and downregulating 
cyclinD1/cyclin‑dependent kinase4 and phosphorylated protein kinase B. In vivo, casticin inhibited tumor growth.
Conclusion: Casticin induces G0/G1 arrest and apoptosis in gallbladder cancer, suggesting that casticin might repre‑
sent a novel and effective agent against gallbladder cancer.
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Background
Gallbladder cancer (GBC) is the most common malig-
nant and fatal tumor of the biliary tract [1]. Diagnostic 
and prognostic markers for this malignancy have not 
been extensively studied, and, due to lack of conspicu-
ous symptoms and physical signs, the majority of patients 
are diagnosed at an advanced and incurable stage [2, 3]. 
Moreover, GBC is resistant to chemotherapy or radio-
therapy, surgical resection is the only potentially effective 
treatment for GBC [4, 5]. As a result, the overall 5-year 
survival rate of GBC is less than 5% [5, 6]. Therefore, the 
development of novel and effective agents for GBC treat-
ment remains a significant challenge.
Flavonoids, which are plentiful in components of human 
diets, such as fruits and vegetables, exhibit extensive biolog-
ical effects, including anti-cancer, anti-inflammatory, anti-
oxidant and anti-viral activities [7]. Casticin, the flavonoid 
extracted from Vitex rotundifolia L, exerts anti-inflam-
matory and anti-cancer activities. Casticin has been com-
monly used as an anti-inflammatory agent for thousands 
of years in traditional Chinese medicine [8]. In addition, 
resent studies has demonstrated that casticin can allevi-
ate smoke-induced acute lung inflammation [9]. In recent 
years, researchers have focused their attention on the anti-
cancer effects of casticin against lung cancer, cervical can-
cer, hepatocellular carcinoma, colon cancer and gastric 
cancer [10–14]. However, the effects and mechanisms of 
casticin on human GBC cells have yet to be characterized.
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In this study, we explored the anti-cancer effect of cas-
ticin on GBC cells and investigated the potential mecha-
nisms mediating these effects. We found that casticin 
induced G0/G1 arrest and apoptosis in gallbladder can-
cer, suggesting that casticin might represent a novel and 
effective agent against gallbladder cancer.
Methods
Reagents and drugs
Casticin was obtained from Sigma-Aldrich (St. Louis, MO, 
USA) (Fig.  1a), dissolved in dimethyl sulfoxide (DMSO), 
and stored at −20 °C. The final DMSO concentration used 
was less than 0.1%. A cell counting kit-8 (CCK-8), Hoechst 
33342, and Rhodamine 123 were purchased from Sigma-
Aldrich. Pan-caspase inhibitor (Z-VAD-FMK) and PI3K 
inhibitor (LY294002) were obtained from Abcam (Cam-
bridge, MA, USA). An annexin V/propidium iodide (PI) 
apoptosis kit was purchased from Invitrogen (Carlsbad, 
CA, USA). TUNEL Apoptosis Assay Kit was purchased 
from Beyotime (Shanghai, China). All antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). All cell culture supplies were obtained from Invitro-
gen Gibco (Carlsbad, CA, USA).
Cell culture
The human GBC cell lines NOZ and SGC996 were pur-
chased from the Cell Bank of the Type Culture Collection 
of the Chinese Academy of Sciences (Shanghai, China). 
NOZ cells were cultured in William’s medium, and 
SGC996 cells were cultured in 1640 medium. All media 
were supplemented with 100  µg/ml streptomycin and 
100 U/ml penicillin (Hyclone, Logan, UT, USA) and 10% 
fetal bovine serum (FBS, Gibco). The cells were cultured 
at 37 °C in a humidified incubator with 5% CO2.
Cell viability assay
The viability of GBC cells treated with casticin was evalu-
ated using a CCK-8 assay. Cells were seeded into 96-well 
plates at a density of 4000 cells/well and were cultured for 
16–24  h. The cells were subsequently treated with vari-
ous concentrations of casticin (0, 0.1, 0.5, 1, 4, 7, 10 µM) 
for 24, 48 or 72 h. After the treatment, CCK-8 (10 µl) was 
added to each well, and the cells were incubated for 3 h 
away from light. Absorbance was measured at 450  nm 
using a microplate reader (Bio-Tek, Norcross, GA, USA). 
Cell viability was calculated using the following formula: 
cell viability =  (OD of control − OD of treatment)/(OD 
of control − OD of blank) * 100%. The assay was repeated 
3 times.
Colony formation assay
The SGC996 and NOZ cells were seeded into 12-well plates 
with casticin (0, 1, 4, 7 µM) for 15 days. Then, the cells were 
fixed with 10% formalin and stained with 0.1% crystal vio-
let (Sigma-Aldrich). After washing, the plates were dried up 
and the colonies (with more than 50 cells) were observed 
under a microscope (Leica, Wetzlar, Germany).
Cell cycle analyses
SGC996 and NOZ cells were treated with casticin (0, 1, 
4, 7 µM) for 48 h. The cells were subsequently collected, 
washed with phosphate-buffered saline (PBS), and fixed 
with 75% ethanol overnight. The cells were then centri-
fuged (1500 rpm, 5 min), incubated with 10 mg⁄ml RNase 
and 1  mg/ml PI at 37  °C for 30  min away from light. 
Ultimately, cell cycle distribution was analyzed by flow 
cytometry (FACSCalibur BD, Bedford, MA, USA).
Annexin V/PI staining assay for apoptosis
SGC996 and NOZ cells were treated with casticin (0, 1, 4, 
7 µM) for 48 h. Then, the cells were collected and washed 
with PBS. After centrifugation (1500 rpm, 5 min), the cells 
were combined with 1× Annexin V binding buffer and 
then incubated with 5  µl Annexin V and PI at 37  °C for 
30 min. Cell apoptosis was measured using flow cytometry.
Hoechst 33342 staining
SGC996 and NOZ cells were treated with casticin (0, 
1, 4, 7  µM) for 48  h. The cells were subsequently fixed 
with 1  ml methanol/acetic acid (3:1) for 20  min. The 
fixed GBC cells were washed with PBS and stained with 
5  µg/ml Hoechst 33342 for 15  min at 37  °C. A fluores-
cence microscope (Leica, Wetzlar, Germany) was used to 
observe the morphological changes.
TUNEL assay
TUNEL assay was performed on GBC cells and paraffin-
embedded tissue sections using the one-step TUNEL 
apoptosis assay kit (Beyotime, Shanghai, China) accord-
ing to the manufacturer’s instructions. After casticin 
treatment, samples were incubated with TUNEL reac-
tion mixture for 1 h at 37 °C in the dark and then washed 
twice in PBS. The condensed or fragmented nuclei of 
apoptotic cells were observed using fluorescence micros-
copy at 400× magnification.
Mitochondrial membrane potential (ΔΨm) assay
The cells were treated with casticin (0, 1, 4, 7  µM) for 
48 h, collected and washed with cold PBS. Then, the sam-
ples were incubated with Rhodamine 123 in a 5% CO2 
incubator at 37 °C for 20 min in the dark. Finally, the cells 
were analyzed by flow cytometry.
Western blot analysis
Western blot analysis was used to evaluate the changes in 
protein expression, as previously described [14]. Proteins 
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were separated using 10% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and were 
then transferred to polyvinylidene difluoride (PVDF) 
membranes. The membranes were blocked for 1  h at 
37  °C and incubated with primary antibodies against 
Bcl-2, Bax, cleaved caspase-9, cleaved caspase-3, cleaved 
PARP, CDK4, protein kinase B (AKT), p-AKT, p27, 
cyclinD1 and GAPDH overnight at 4 °C. Next, the mem-
branes were incubated with secondary antibodies for 1 h 
at 37  °C. Proteins were observed using a Gel Doc 2000 
(Bio-Rad, USA).
In vivo tumor xenograft study
Male nude mice (aged 4–6  weeks, weighted 18–22  g) 
were purchased from Shanghai SLAC Laboratory Animal 
Co Ltd (Shanghai, People’s Republic of China). The ani-
mals were housed at 25 ± 2  °C at a relative humidity of 
70 ± 5% under natural light/dark conditions for 1 week 
and were allowed free access to food and water. NOZ cells 
(at a density of 1 × 106 cells in 0.2 ml) were injected into 
the right axilla of each mouse. Twenty-four hours later, 
the mice were randomly divided into 3 groups (control, 
10, 20 mg/kg; 7 mice per group). Mice in control group 
Fig. 1 Casticin inhibits the proliferation and viability of NOZ and SGC996 cells. a The chemical structure of casticin. b, c NOZ, SGC996 and 293T cells 
were treated with various concentrations of casticin (0, 0.1, 0.5, 1, 4, 7 µM) for 24, 48 or 72 h. Cell viability was assessed using the CCK‑8 assay. d NOZ 
and SGC cells were exposed to 1 µM casticin for 24 h, 48 or 72 h. f, g Casticin suppressed colony formation of NOZ and SGC996 cells. Cells were 
exposed to casticin (0, 1, 4, 7 µM) and were allowed to form colonies for 14 days. All data are presented as the means ± standard deviations, and 
each experiment was repeated 3 times. Significant differences compared with the control are indicated by *p < 0.05, **p < 0.01, and ***p < 0.001
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were intraperitoneally injected with (10% DMSO + 90% 
PBS). The other groups received administered casticin 
(10 or 20 mg/kg) every 2 days for up to 25 days. On day 
26, the animals were sacrificed, and the tumors were dis-
sected and weighed. The animal experiments were per-
formed in strict accordance with international ethical 
guidelines and the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals (SYXK [Shang-
hai] 2013-0106).
Immunohistochemistry and HE staining
After the mice were sacrificed, tumors from the nude 
mice treated with different concentrations of casticin were 
resected and immediately fixed in 10% formalin, embedded 
in paraffin, cut into 5 mm sections and mounted on slides. 
The expression patterns of Ki67, cyclinD1 and p-Akt were 
analyzed using immunohistochemical streptavidin-peroxi-
dase staining (IHC) and hematoxylin and eosin (HE) stain-
ing was used for histopathological examination.
Statistical analysis
All experiments were performed at least 3 times, and the 
results are expressed as the means ± standard deviations 
unless otherwise stated. The Student’s t test was used to 
compare the differences between the treated groups and 
the corresponding control groups. p  <  0.05 was consid-
ered statistically significant.
Results and discussion
Casticin inhibits the proliferation and viability of NOZ 
and SGC996 cells
Cell proliferation was evaluated using the CCK-8 assay, 
which demonstrated that NOZ and SGC996 cell prolif-
eration rates were significantly inhibited by casticin in a 
dose- and time-dependent manner (Fig.  1b–d). How-
ever, casticin treatment did not significantly inhibit 293T 
viability (Fig. 1e). The inhibition of casticin-treated GBC 
cells was moderate at 48  h, and the IC50 of NOZ and 
SGC996 cells was approximately 2 µM at 48 h. Therefore, 
we selected 1, 4 and 7 µM as the concentrations to use in 
subsequent experiments. The colony formation assay was 
used to detect the proliferation of single cell. The NOZ 
and SGC996 cells were treated with at various concentra-
tions (0, 1, 4, 7 µM) for about 2 weeks. As shown in Fig. 1f, 
g, the number and size of colonies derived from casticin-
treated cells were markedly smaller compared with the 
control group. These data demonstrate that casticin can 
inhibit the proliferation and viability of GBC cells.
Casticin induces mitochondrial‑dependent apoptosis 
in NOZ and SGC996 cells
We investigated the effect of casticin on apoptosis in 
GBC cells using flow cytometry and Hoechst 33342 
staining. Compared with the control group, the percent-
ages of casticin-treated cells in the early and late apop-
tosis stages were strikingly elevated in a dose-dependent 
manner (Fig.  2a–c). In a subsequent experiment, we 
treated NOZ and SGC996 cells with various concentra-
tions (0, 1, 4, 7 µM) for 48 h, and stained the cells with 
Hoechst 33342. As shown in Fig. 2d, the casticin-treated 
cells exhibited markedly increased chromatin condensa-
tion and fragmentation compared with the control group, 
in which cells were round and homogeneously stained. 
The result was consistent with the flow cytometry data, 
and together, these data indicate that casticin can induce 
apoptosis in NOZ and SGC996 cells. TUNEL analysis 
also showed more apoptotic cells in casticin-treatment 
GBC cells (Fig. 2e).
Mitochondrial damage to cells results in perturbation 
of the mitochondrial membrane potential (ΔΨm) [15]. 
We evaluated changes in the ΔΨm in NOZ and SGC996 
cells using Rhodamine 123 staining, as the decrease in 
the intensity of Rhodamine 123 staining reflects mito-
chondrial membrane potential and integrity. As shown in 
Fig. 3a, b, ΔΨm decreased in a dose-dependent manner, 
indicating that casticin induces mitochondrial-depend-
ent apoptosis.
Caspases play critical roles in apoptosis initiation and 
maintenance [16, 17]. We explored the potential mecha-
nism of casticin-induced apoptosis using western blot 
analysis. As shown in Figs. 3c and 4d, cleaved caspase-3, 
-9, -PARP, Bax and p27 were upregulated following expo-
sure to casticin in a dose-dependent manner, whereas, 
Bcl-2, p-Akt and Bcl-2/Bax level significantly decreased 
compared with the control group. To confirm the results, 
we evaluated cell viability after treatment with casticin 
in the presence or absence of Z-VAD-FMK, a caspase 
inhibitor. As shown in Fig. 3d, Z-VAD-FMK can abolish 
casticin cytotoxicity in GBC cells. Together, these results 
indicate that casticin induces mitochondrial-dependent 
apoptosis in NOZ and SGC996 cells.
Casticin induces G0/G1 arrest and inhibits proliferation 
regulated by an inactive AKT pathway
To determine whether casticin influences cell cycle pro-
gression, we investigated cell cycle distribution by flow 
cytometry. The results indicated that the proportions 
of G0/G1 cells increased in a dose-dependent man-
ner in NOZ and SGC996 cells, indicating that casticin 
induced G0/G1 arrest (Fig. 4a–c). To further investigate 
the effect of casticin on cell cycle progression, we exam-
ined cycle-related protein expression using western blot 
analysis. Casticin treatment resulted in decreased lev-
els of cyclinD1 and CDK4, consistent with a G0/G1 cell 
cycle arrest (Fig. 4d). A recent study identified p27 as an 
important cyclin-dependent kinase inhibitor that inhibits 
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Fig. 2 Casticin induces mitochondrial‑dependent apoptosis in NOZ and SGC996 cells. a–c NOZ and SGC996 cells were treated with casticin (0, 1, 
4, 7 µM) for 48 h. The Q3 quadrant (Annexin V−/PI−), Q4 quadrant (Annexin V+/PI−), and Q2 quadrant (Annexin V+/PI+) indicate the percent‑
ages of normal cells, cells in early apoptosis, and cells in late apoptosis, respectively. d NOZ and SGC996 cells were exposed to casticin for 48 h, and 
nuclear morphological changes associated with apoptosis were evaluated by Hoechst 33342 staining. d–f Representative images of TUNEL assay 
of different casticin‑treatment in GBC cells. All data are presented as the means ± standard deviations and each experiment was repeated 3 times. 
Significant differences compared with the control are indicated by *p < 0.05, **p < 0.01, and ***p < 0.001
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the activation of cyclin D-CDK4 complexes and induces 
cell cycle arrest at the G0/G1 and G2/M phases [18]. In 
addition, Akt pathway regulates cell cycle progression 
and cell proliferation by influencing p27, and the results 
presented in Fig. 4d was consistent with these findings.
To determine if casticin-induced proliferation inhibi-
tion was regulated by inhibiting of Akt activity, we eval-
uated cell viability after treatment with casticin in the 
presence or absence of LY294002, a PI3K/Akt inhibitor. 
As shown in Fig. 4e, LY294002 enhanced GBC cells death. 
To further confirm the results, we transiently transfected 
wild-type Akt and constitutively active Akt into GBC 
cells, and then we treated with casticin and evaluated the 
viability. As shown in Fig. 4f, overexpression of wild-type 
Akt and constitutively active Akt can abolish casticin 
cytotoxicity in GBC cells.
Therefore, we conclude that casticin induces G0/G1 
arrest via Akt signaling pathway, and that the modulation 
of Akt signaling also accounts for the anti-proliferative 
effect of casticin.
Casticin inhibits tumor growth in vivo
To evaluate the anti-cancer effect of casticin in  vivo, 
we injected mice with 10% DMSO  +  90% PBS (con-
trol group) or casticin at a concentration of either 10 
or 20  mg/kg every 2  days after their inoculation with 
NOZ cells. We found that casticin inhibits tumor 
growth in a dose-dependent manner (Fig.  5a, b). Based 
Fig. 3 Casticin induces mitochondrial‑dependent apoptosis in NOZ and SGC996 cells. a, b Flow cytometry analysis of the mitochondrial mem‑
brane potential (ΔΨm). NOZ and SGC996 cells were treated with casticin (0, 1, 4, 7 µM) and stained with Rhodamine 123. Cells with high ΔΨm are 
marked “survival”, and those with low ΔΨm are marked “apoptosis”. The percentages of cells with low ΔΨm (apoptosis) are shown. c Apoptosis‑
related proteins in NOZ and SGC996 cells were analyzed by western blot. GAPDH was used as a loading control. d After pretreatment with 5 mM 
Z‑VAD‑FMK for 1 h, GBC cells were incubated with 4 µM casticin for 24 h, and cellular viability was determined. All data are presented as the 
means ± standard deviations. Significant differences compared with the control were indicated by *p < 0.05, **p < 0.01, and ***p < 0.001
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on this observation, we performed western blot analy-
sis, HE and IHC analysis. As shown in Fig.  5c–e, Bcl-2, 
cyclinD1, p-AKT and ki-67 expression levels were strik-
ingly reduced, and Bax expression level was significantly 
elevated in casticin-treated groups compared with the 
control group. Moreover, tunel analysis showed more 
apoptotic cells in casticin-treated groups compared with 
the control group (Fig. 5f ). These results are consist with 
the in vitro effects of casticin.
GBC is the most common and fatal cancer in biliary 
system, and surgical resection is the only effective treat-
ment option. Thus, it is essential to identify novel effec-
tive treatments for GBC. Traditional Chinese medicine 
has been extensively used to treat various diseases for 
thousands of years. As an active compound isolated 
from Vitex Fructus, casticin can inhibit proinflamma-
tory cytokines and inflammatory mediators, such as NO 
and PGE2, by blocking the activation of NF-ΚB, Akt, and 
MAPK signaling [19]. Recent studies have shown that 
casticin inhibits proliferation and induces apoptosis in 
various cancer cells in vitro. However, there have been no 
in vivo tumor xenograft studies evaluating the anti-can-
cer effect of casticin. In this study, we investigated NOZ 
and SGC996 cell proliferation and viability using CCK-8 
analysis and colony formation assays. We found that 
casticin can inhibit NOZ and SGC996 cell proliferation, 
and casticin cannot significantly inhibit 293T cell viabil-
ity. Therefore, we propose that casticin represents a new 
and promising therapeutic agent for gallbladder cancer. 
Moreover, we evaluated the effect of casticin treatment in 
mice with xenografted tumors. Based on the weight and 
volume of the tumors, we conclude that casticin exerts 
anti-cancer activity in GBC in  vivo. In addition, the 
expression of related proteins expression using western 
blot analysis, HE and IHC staining, the results of which 
were in accordance with our in vitro assays.
Fig. 4 Casticin induces G0/G1 arrest by inactiving the AKT pathway. a–c NOZ and SGC996 cells were treated with casticin (0, 1, 4, 7 µM) for 48 h. 
The cell cycle distribution was analyzed by flow cytometry. d Expression levels of cyclinD1, CDK4, p27, p‑AKT and AKT were measured using west‑
ern blot analysis. e After pretreatment with 50 µM LY294002 (Akt inhibitor) for 1 h, GBC cells were incubated with 4 µM casticin for 24 h, and cellular 
viability was determined. f Cellular viability was determined after treatment with 4 µM casticin in cells transfected with WT‑Akt, CA‑Akt, or vehicle 
plasmid. All data are presented as the means ± standard deviations. Significant differences compared with the control were indicated by *p < 0.05, 
**p < 0.01, and ***p < 0.001
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We also evaluated the effect of casticin on apoptosis 
using flow cytometry, Hoechst 33342 staining and tunel 
analysis. Apoptosis is generally characterized as specific 
morphological changes, such as cell shrinkage, nuclear 
or cytoplasmic fragmentation, chromatin condensation 
and the formation of dense bodies that are phagocytosed 
by neighboring cells [20]. As shown in Fig. 2d, NOZ and 
SGC996 cells treated with casticin exhibited markedly 
Fig. 5 Casticin inhibits tumor growth in vivo. a Different concentrations (10% DMSO + 90% PBS, 10 and 20 mg/kg) casticin were injected into 
nude mice after inoculated NOZ cells every 2 days. Images of 5 representative mice (n = 7) from each group are presented to show the sizes of the 
resulting tumors. b Tumors were excised from the animals and weighed. c–e Bcl‑2, cyclinD1, p‑AKT and Ki‑67 expression levels were analyzed using 
HE, IHC staining and western blot analysis. f Representative images of TUNEL assay of tumor xenografts (original magnifications: ×400). All data are 
presented as the means ± standard deviations. Significant differences from the control were indicated by *p < 0.05, **p < 0.01, and ***p < 0.001
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increased chromatin condensation and fragmentation 
compared with the control group cells, which were round 
and homogeneously stained. In addition, the proportions 
of cells in early and late apoptosis stages in the casticin-
treated groups were strikingly elevated in a dose-depend-
ent manner.
Various mechanisms have been suggested to contrib-
ute to the progression of gallbladder cancer, in particular 
mutations in components of cell cycle or apoptotic path-
ways, and the processes of signal transduction, angio-
genesis, invasion, and metastasis [21–23]. Apoptosis 
signaling cascades can be divided into 2 major pathways: 
a death-receptor-induced extrinsic pathway and a mito-
chondria-apoptosome-mediated intrinsic pathway [24]. 
In this study, we found that mitochondrial-dependent 
apoptosis was involved in casticin induced apoptosis. Bax 
and Bcl-2 are important regulators of the mitochondria-
mediated apoptosis pathway, and the balance of these 
2 factors is crucial for cell survival and cell death. The 
antiapoptotic factor Bcl-2 has been shown to prevent 
apoptosis by forming a heterodimer with proapoptotic 
factors, such as Bax, resulting in proapoptotic effects 
[25]. Activation of Bcl-2 family proteins can induce the 
mitochondrial permeabilization, and can induce cas-
pase-9 activation, which subsequently induces the cleav-
age of procaspase-3 [26]. Caspase-3 is a key executioner 
caspase that it is capable of cleaving many important cel-
lular substrates, including PARP [27]. In this study, we 
demonstrated that Bax expression significantly increased 
and that Bcl-2 expression decreased in response to cas-
ticin treatment both in vitro and in vivo. In addition, cas-
ticin significantly enhanced the enzymatic activity levels 
of caspase-3, caspase-9 and PARP (Fig.  3c). Moreover, 
ΔΨm decreased in a dose-dependent manner after 48 h 
of incubation with casticin. Together, these results sug-
gest casticin induced apoptosis occurs through the mito-
chondria-dependent pathway.
The induction of cell cycle arrest at a specific check-
point and thereby inducing apoptosis is a common 
mechanism for the cytotoxic effects of anticancer drugs 
[28]. In this study, we investigated cycle distribution 
using flow cytometry. The data showed that the propor-
tion of G0/G1 cells increased in a dose-dependent man-
ner, indicating that casticin can induce G0/G1 arrest. 
Cell cycle progression is highly regulated by a series of 
cell cycle checkpoint proteins, such as the cyclins and 
CDKs. Among these proteins, cyclinD and E, together 
with CDK2, CDK4, or CDK6, play major roles in DNA 
replication and mitosis by regulating G0/G1 phase of the 
cell cycle [29]. Therefore, we investigated the expression 
of cylinD1 and CDK4 in casticin-treated GBC cells and 
found that cyclinD1 and CDK4 contributed to G0/G1 
arrest.
The PI3K/AKT pathway is one of the major signal-
ing pathways involved in the progression of various 
tumors and is associated with cancer progression and 
invasion [30]. AKT is a key downstream effector of 
PI3K and is down-regulated in various cancers, includ-
ing osteosarcoma and prostate cancer [31]. Previous 
studies have demonstrated that Akt inactivation might 
inhibit the expression of proteins associated with events 
that mediate the cancer development and progression, 
including apoptosis and cell cycle progression [29, 32, 
33]. In our study, the results of the western blot analy-
sis demonstrated that casticin significantly decreased 
p-Akt expression and that this effect was accompanied 
by an increase in p27. Inactivation of Akt leads to the 
increased expression of p27, and decreased expression 
of cyclinD1/CDK4 decreased, which contributed to G0/
G1 arrest. Furthermore, Akt inactivation can lead to 
upregulation of Bad expression and the downregulation 
of Bcl-2 expression, which associated cell apoptosis. In 
summary, we suggest that the Akt signaling pathway is 
involved in casticin-induced cell apoptosis and cell cycle 
arrest.
Conclusions
Taken together, these findings indicate that the Akt 
signaling pathway is involved in casticin-induced cell 
apoptosis and cycle arrest. Furthermore, the intrinsic 
mitochondrial pathway is involved in casticin-induced 
apoptosis. Therefore, we suggest that casticin might be a 
novel and effective therapy for GBC.
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